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Clinical overview
Pharmacological management of unipolar
depression
Malhi GS, Hitching R, Berk M, Boyce P, Porter R, Fritz K.
Pharmacological management of unipolar depression.
Objective: To be used in conjunction with ‘Psychological management of
unipolar depression’ [Lampe et al. Acta Psychiatr Scand 2013;127(Suppl.
443):24–37] and ‘Lifestyle management of unipolar depression’ [Berk
et al. Acta Psychiatr Scand 2013;127(Suppl. 443):38–54]. To provide
clinically relevant recommendations for the use of pharmacological
treatments in depression derived from a literature review.
Method: Using our previous Clinical Practice Guidelines [Malhi et al.
Clinical practice recommendations for bipolar disorder. Acta Psychiatr
Scand 2009;119(Suppl. 439):27–46] as a foundation, these clinician
guidelines target key practical considerations when prescribing
pharmacotherapy. A comprehensive review of the literature was
conducted using electronic database searches (PubMed, MEDLINE),
and the findings have been synthesized and integrated alongside clinical
experience.
Results: The pharmacotherapy of depression is an iterative process that
often results in partial and non-response. Beyond the initiation of
antidepressants, the options within widely used strategies, such as
combining agents and switching between agents, are difficult to
proscribe because of the paucity of pertinent research. However, there is
some evidence for second-line strategies, and a non-prescriptive
algorithm can be derived that is based broadly on principles rather than
specific steps.
Conclusion: Depression is by its very nature a heterogeneous illness that
is consequently difficult to treat. Invariably, situation-specific factors
often play a significant role and must be considered, especially in the
case of partial and non-response. Consulting with colleagues and
trialling alternate treatment paradigms are essential strategies in the
management of depression.
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Clinical recommendations
• Major depression is a heterogeneous disorder that requires both empirical evidence and clinical
experience when treating.
• Patient adherence is essential and should be appreciated by the patient and monitored by the physician.
• For partial and non-response, physicians should re-evaluate the diagnosis, consider alternate
treatment paradigms and, if necessary, consult colleagues.
Additional comments
• The proposed algorithm and recommendations should be used in conjunction with other recognized
sources to guide the management of depression.
• The recommendations set out in this supplement are intended for adults who suffer from unipolar
depression. Special populations, such as adolescents, pregnant women and the elderly, are not
discussed in detail.
• This review is not intended to be a comprehensive guide to antidepressant medication.
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Introduction
Pharmacotherapy is an important component
within the biopsychosocial and lifestyle approach
to treating depression. It builds upon the ‘SET A
PACE’ approach (1), and in doing so, expands the
5P Model, which is a widely used approach for
formulation. The latter considers the presenting
problem alongside predisposing, precipitating, per-
petuating and protective factors and adopts a
longitudinal personalized perspective (2). In addi-
tion to psychological interventions (3) and lifestyle
management (4), which are addressed in separate
articles of this supplement, pharmacotherapy is an
important treatment option that can be the key
ingredient for reaching remission. However, it
requires informed administration and monitoring
and may not be effective for all individuals.
The practical issues of medication choice, partial
and non-response to an initial antidepressant treat-
ment, and pharmacological strategies beyond
prescription of the initial medication are major
concerns in clinical practice and form the focus of
this article. Pharmacotherapy treatment strategies
for achieving optimal response and managing
potential non-response are discussed and
addressed by drawing upon both research evidence
and clinical experience. The latter is particularly
important when considering complex management
decisions in which research remains challenging.
Aims of the study
The study aims to provide clinically relevant,
evidence-based recommendations for an individu-
alized formulation for pharmacotherapeutic
management.
Material and methods
Using our previous Clinical Practice Guidelines (1)
as a foundation, these clinician recommendations
target key practical considerations when prescrib-
ing pharmacotherapy. A comprehensive review of
the literature was conducted using electronic data-
base searches (PubMed, MEDLINE), and the find-
ings have been synthesized and integrated along
with clinical experience.
Results
Understanding depression and its context
To develop an appropriate management plan, it is
essential to understand the context in which
depression emerges and this can be facilitated by
use of the 5PModel. The aim is essentially to build
a detailed ‘picture of the problem’ and tailor treat-
ment accordingly. When applying the 5P Model to
pharmacotherapy, predisposing factors include past
treatments and prior response. With respect to the
latter, pharmacological sensitivity to specific medi-
cations is likely to be determined by the unique
biology of an individual. Pharmacogenomics
addresses this very issue and although this field is
in its infancy, it is likely to have mainstream appli-
cation in the future (5). Precipitating factors are
more predictable and include non-compliance,
medical disorders, especially inflammatory disor-
ders, ineffective treatments and iatrogenic causes,
for example, the side-effects of medications used to
treat diseases (levodopa, a drug for Parkinson’s
disease or interferon). Further, it is important to
note that with long-term medication, antidepres-
sant effects are intended to be protective, and any
associated side-effects are likely to become more
pronounced with remission and can seemingly
perpetuate symptoms. A detailed correctly mapped
out 5P Model is essential for optimal treatment,
and misidentifying the 5Ps can result in compro-
mising and prolonging treatment.
Partial and non-response are exceedingly com-
mon and as will be discussed later, response rates
to pharmacotherapy differ based on individual
characteristics. This no doubt contributes to poor
response, and although some patients respond well
after only one treatment trial, most require multi-
ple treatment trials before achieving remission. For
those who respond only partially, or not at all, to
multiple pharmacotherapeutic trials, re-evaluation
should be considered alongside consultation with a
colleague. Reviewing the 5P Model is useful
because there are often additional features (i.e. per-
sonality issues, anxiety symptoms, persisting inter-
personal or psychosocial problems) that may help
explain why the patient is not recovering. This
study aims to outline the pharmacotherapeutic
options for the treatment of depression at each
stage of management including initial choice of
medication, strategies for negotiating partial or
non-response to initial medication, and suggestions
for when patients do not reach remission following
multiple therapeutic trials. Therefore, evaluating
and monitoring treatment response is important,
and standardized rating scales are useful for assess-
ing change. In this regard, a unidimensional scale,
such as the Bech–Rafaelsen Melancholia Scale (6),
or non-unidimensional scales like the Hamilton
Depression Scale (HAM-D) (7), the Montgomery–
Asberg Depression Rating Scale (MADRS) and
the Inventory of Depressive Symptomatology are
of particular benefit. Asking the patient to rate
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their mood on a 0–10 scale is practical way of
charting treatment response.
Pharmacotherapy
Our clinical practice recommendations (1) for the
management of unipolar non-psychotic depression
highlight the need to assess what factors may influ-
ence treatment response and prognosis. It is impor-
tant to be able to foresee the patient’s treatment
outcome (prognosis) when initiating treatment.
The features to consider can be recalled with the
mnemonic 4C, which represents the four actions,
each of which begins with the letter ‘c’: characterize
– identify the clinical symptoms and subtype;
calibrate – gauge the severity and chronicity of the
symptoms; corroborate – identify any comorbidi-
ties and the context that is contributing to the
illness; and consider – identify coping styles and
adaptive features. Identifying factors that are likely
to influence treatment outcome in combination
with a detailed 5P Model helps guide which phar-
macological treatment is most likely to be effective
for a particular patient at a specific juncture and
which patients would not benefit from antidepres-
sant medication.
Selecting an antidepressant. There are a large vari-
ety of antidepressant medications, all of which
have similar efficacy when treating community-
based depression (8); however, they differ in terms
of tolerability and response to specific features of
depression (e.g. anxiety, insomnia) (Table 1). To
assist in selecting which option would most likely
benefit the patient, our previous recommendations
that evaluate antidepressants on the basis of risk,
adherence, tolerability and efficacy (RATE) remain
pertinent (1).
Risk: Tricyclics antidepressants (TCAs), mono-
amine oxidase inhibitors (MAOIs) and the
serotonin and noradrenaline reuptake inhibitor
(SNRI) venlafaxine, in particular, carry high
risks of toxicity in overdose and interactions
with other medications. Therefore, alternative
antidepressants, in particular selective serotonin
reuptake inhibitors (SSRIs), are a much safer
and consequently a more popular treatment
option (Table 2).
Adherence: Treatment adherence is essential,
but remarkably difficult to achieve, particularly
longer term. In this regard, medication choice is
critical, and the dosing of medications should be
simple and convenient, and side-effects need to
remain minimal to facilitate adherence/compli-
ance. Patient preference should always be con-
sidered, as it will facilitate adherence.
Tolerability: Tolerability is intertwined with
adherence. Medication side-effects impact toler-
ability, which, in turn, affects adherence. There-
fore, common treatment side-effects should be
discussed with the patient at the outset of treat-
ment and side-effects should be assessed rou-
tinely. Starting on a low dose will help in
minimizing side-effects early in treatment.
Efficacy: Efficacy remains the sine qua non of
any treatment option, but the clinical effects of
antidepressants can take 7–10 days to emerge,
and therefore, to ensure adherence, patients
must be made aware of the likely delay.
Risk, adherence and tolerability are prioritized
because most antidepressant options are equally
effective when treating clinical depression of mild-
to-moderate severity (Fig. 1). SSRIs are undoubt-
edly better tolerated and less complicated to
administer than older antidepressants, and hence
adherence is better. Contrasting SSRIs and older
antidepressants in terms of efficacy provides per-
haps the only example of a significant gradient or
difference in potency among the antidepressant
armamentarium. However, this differential is only
discernible with melancholia and psychotic
depression (9).
Further, the first and foremost consideration in
pharmacotherapy is safety. In this regard, antide-
pressants, especially SSRIs, are relatively safe, yet
adverse effects can never be fully ruled out. For
instance, the potential risk of increasing self-harm
in the initial stages of treatment, especially in
youth, continues to be a concern. Research sug-
gests there is a small trend for increased suicidality
in young adults (18–24 years), but that equally
there is reduced risk and increased protective
effects of SSRIs and newer antidepressants on sui-
cide attempts in adults (10, 11). As mentioned pre-
viously, adherence is necessary for any medication
to be effective, and thus is essential to gain thera-
peutic benefit. Early discontinuation rates are high
(12, 13), even though guidelines recommend that
the minimum duration of antidepressant treatment
for depression should be 6–12 months. During this
time, approximately 30% of patients discontinue
within the first 30 days and more than 40%
discontinue within 90 days of treatment (13).
Given the high discontinuation rates, it is impor-
tant to optimize adherence to treatment, especially
when prescribing antidepressants that are likely to
produce significant side-effects. Strategies such as
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education, self-management by patients and col-
laborative care by practitioners have been shown
to enhance patient adherence (14). Side-effects are
one of the main reasons cited for early discontinu-
ation of antidepressants; thus, tolerability is essen-
tial and this is the domain (as opposed to efficacy)
in which most antidepressants differentiate from
each other.
The SSRIs, SNRIs and some newer agents (such
as agomelatine) are recommended first-line
because they have better safety and tolerability
profiles than older antidepressants, such as the
TCAs and MAOIs (15–17). The variety of first-line
medications makes initiating treatment a process
that requires careful consideration. Meta-analyses
have revealed modest differences in efficacy
Table 1. Summary of antidepressant clinical use, principal mechanisms of action and key features of depression for which the medication is useful
Antidepressant class Generic name of medication Principal mechanism of action
Features of depression for
which medicine is particularly useful
1st line SSRI (120–128) Selective 5-HT uptake
blockade
Anxiety
NARI (129–131) Reboxetine, Atomoxetine Reuptake inhibitor for
norepinephrine and
epinephrine
Reboxetine may be useful for activation.
Atomoxetine is prescribed for ADHD
and is therefore not recommended
1st line for depression.
NaSSA Mirtazapine Blocks the reuptake of
serotonin via 5-HT2A
and 5-HT2C receptors
Insomnia
Agomelatine Melatonergic agonist
and 5-HT2C antagonist
Sleep problems
NDRI Bupropion Blocks the action of the
norepinephrine transporter
and dopamine transporter
Melancholia; severe depression
2nd line SNRI (132) Venlafaxine†,
Desvenlafaxine, Milnacipran
and Duloxetine
Similar to TCAs but lack broad
spectrum properties
Melancholia; severe depression
Venlafaxine: anxiety
Duloxetine: pain
TCA (121–125, 133–135) Amitriptyline, Clomipramine Block reuptake of multiple
monoamines
Pain
Melancholia
Nefazodone 5-HT2A antagonist
3rd line MAOI Irreversibly inhibit the
mitochondrial enzymes
Monoamine oxidase A
(prefers 5-HT) & B (prefers NA & EPH)
Melancholia
Atypical symptoms*
Treatment resistant depression
Adjunctive SARI Trazodone Blocks reuptake of serotonin,
noradrenaline and/or dopamine
Used when patients do not respond
well to 1st line
SSRI, selective serotonin reuptake inhibitor; NARI, noradrenaline reuptake inhibitor; NaSSA, noradrenaline and specific serotonergic antidepressant; NDRI, norepinephrine-dopa-
mine reuptake inhibitor; SNRI, serotonin and noradrenaline reuptake inhibitor; TCA, tricyclics antidepressant; MAOI, monoamine oxidase inhibitor; SARI, serotonin antagonist and
reuptake inhibitors; NA, noradrenaline; EPH, epinephrine.
*Evidence is equivocal.
†Low dose.
Table 2. Side-effects associated with common antidepressant groups. +, ++, +++: <10%, 11–29%, >30%
Weight gain
Sexual
dysfunction
CNS effect
(e.g. sedation, fatigue)
Anticholinergic effect
(e.g. dry mouth, tremor) GI distress
SSRI + +++ ++ ++ ++
NARI ++ + + + +
NaSSA ++ ++ +++ ++ +
Agomelatine + + + + +
NDRI ++ + ++ ++ +
SNRI + ++ ++ ++ +++
TCA ++ + + ++ +
MAOI* + + + + +
Nefazodone + + ++ ++ ++
SARI + + +++ + ++
SSRI, selective serotonin reuptake inhibitor; NARI, noradrenaline reuptake inhibitor; NaSSA, noradrenaline and specific serotonergic antidepressant; NDRI, norepinephrine-dopa-
mine reuptake inhibitor; SNRI, serotonin and noradrenaline reuptake inhibitor; TCA, tricyclics antidepressant; MAOI, monoamine oxidase inhibitor; SARI, serotonin antagonist and
reuptake inhibitors.
*MAOIs require dietary restrictions to prevent hypertensive crisis, some combinations with other drugs can be fatal.
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between newer antidepressants, such as venlafaxine
over SSRIs (8), escitalopram over comparators
(18) and sertraline over other antidepressants (19).
However, tolerability has shown to be inferior in
venlafaxine compared with SSRIs (20). In trials, it
is difficult to establish superior efficacy of one med-
ication over another because of the large sample
sizes this requires. Hence, most research groups
have not systematically compared the efficacy of
individual agents but instead compared the effects
against placebo. Pharmaceutical companies have
conducted the majority of comparison studies, lar-
gely for registration. Overall, escitalopram, mirt-
azapine, sertraline and venlafaxine have some
benefits as compared to other antidepressants
when considering dosage and severity of the
depressive episode, and reboxetine is the only anti-
depressant to have a significantly lower response
rate than other agents (21, 22).
Other factors to consider when choosing an
antidepressant include the symptom profile, medi-
cal and psychiatric comorbidity, previous
response to antidepressants, patient preference
and cost of treatment. Additionally, drug–drug
interaction is an important consideration (partic-
ularly when medical comorbidity exists), espe-
cially because it can increase side-effects and loss
of efficacy can result (23). Selection should also
take into consideration the prevailing symptoms,
such as insomnia and anxiety, because particular
antidepressants may be better suited to treating
specific symptoms because of their unique chemi-
cal profile. For example, mirtazapine is often sed-
ative (as a result of its effect on histaminic
receptors) and therefore may be of benefit where
insomnia is a prominent symptom (but balanced
against weight gain), and reboxetine may be use-
ful in drive-deficient ‘anergic’ states where sus-
tained motivation is lacking. Depressed patients
who suffer from a disturbed sleep–wake cycle
may benefit from agomelatine because of its abil-
ity to improve both night-time sleep and daytime
functioning (24). Escitalopram is an antidepres-
sant that is also used for anxiety disorders, thus
is favourable for depressed patients where anxiety
is a prominent symptom (Table 1).
Initializing treatment. Once it has been determined
that the patient would benefit from antidepressants
and a specific medication has been chosen, prior to
commencing the medication the patient should be
informed about possible side-effects (in particular,
the possibility of activating side-effects and agita-
tion initially), the importance of adherence, the
delay prior to the antidepressant becoming effec-
tive and self-management techniques, which is
designed to foster personal empowerment and
responsibility. The patient should give consent to
treatment and this should be recorded. Where pos-
sible it is helpful to include a significant other in
the initiation of treatment. Planned follow-up
should be scheduled with regular monitoring of
side-effects and adjustment of treatment dosage as
needed.
The patient (and carer) may choose to keep a
mood diary to self-monitor their progress in which
they can record their mood on a simple 0–10 scale
(it is now possible to do this using a smart phone
app).
Monitoring response. In clinical practice, response
is easily gauged as simply ‘getting better’. How-
ever, to objectively assess the efficacy of medica-
tion, the use of both observer-rated and self-rated
questionnaires can be useful. The latter are com-
monly used in research settings and in recent years
have become more widely adopted in general prac-
tice and primary care practice.
When measuring the efficacy of medication, a
50% improvement on rating scales (e.g. HAM-D
or a self-report scale) is typically the point used to
define a clinical response, even though, in reality,
this may not equate to substantive clinical
improvement. Measuring and tracking efficacy
rates in patients can be difficult, and the process is
further complicated because the trajectory of
response is unique in every case. Ideally, both ini-
tial (Fig. 2) and long-term responses (Fig. 3)
should be charted to determine the likely outcome
and establish whether the current treatment is pro-
viding sufficient benefit to the patient.
SSRIs
NARIs
NASSAs
Agomela
NDRI
SNRIs*
TCAs
MAOIs
Nefazodone
SARIs _ 0 +
First-line 
Second-line 
Clinical u lity depressants
Legend
Acute efficacy
Tolerability difficul es
Fig. 1. The clinical utility of antidepressant agents rated
according to efficacy and tolerability. *Efficacy for SNRIs is
plotted for severe depression. SSRI, selective serotonin reup-
take inhibitor; NARI, noradrenaline reuptake inhibitor;
NaSSA, noradrenaline and specific serotonergic antidepres-
sant; NDRI, norepinephrine-dopamine reuptake inhibitor;
SNRI, serotonin and noradrenaline reuptake inhibitor; TCA,
tricyclics antidepressant; MAOI, monoamine oxidase inhibitor;
SARI, serotonin antagonist and reuptake inhibitors. Adapted
from Clinical practice recommendations for depression (1).
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After commencing antidepressant treatment,
there is usually a delay of 7–10 days before a dis-
cernible response emerges (25, 26) and, in practice,
evidence of an antidepressant effect is most likely
to occur within the first 2 weeks of treatment (25–
27). Figure 2 shows the initial patterns of response
that are common following the commencement of
treatment. Remission following treatment of the
first antidepressant trial, as illustrated by curve A,
only occurs in a quarter to a third of patients with
major depression (28).
In some patients, there may be considerable
delay before symptoms improve (curve A2). There-
fore, it is important to administer an adequate dos-
age during a trial of 2–4 weeks, while ensuring
compliance.
However, approximately two-thirds of patients
who begin treatment for depression experience
either partial response (curve B and B2) or no
response (curve C), as demonstrated by a 20–50%
reduction on a depression rating scale. Both
groups will be discussed in further detail below.
When such a scenario occurs, key medication strat-
egies include i) switching, ii) augmentation, iii)
combination treatment, and iv) alternative options.
There are a range of pharmacological interventions
that are more suitable at each stage of iteration,
and as discussed in more detail later, there is con-
siderable evidence to support the efficacy of each
strategy. However, there is little information as to
how the strategies compare against each other or
sequencing specificities, especially in the case of
partial response. Therefore, the following sugges-
tions are based on expert opinion.
Following the initial response to an antidepres-
sant, the long-term response is equally variable
(Fig. 3). Once a patient shows short-term improve-
ment, the symptoms either continue to improve
and reach remission, or the response plateaus.
When the latter scenario occurs, a treatment
strategy change may be necessary. The STAR*D
study (28) showed that with successive trials of an-
tidepressants, a cumulative response rate of 60%
can be achieved, although it may require 2–3 anti-
depressant trials before remission is reached. Long-
term response patterns also show that despite
switching to an alternative medication or adding an
augmenting agent, a significant proportion of
patients with depression still only achieve a partial
response (B, C) or may remain refractory (D).
These patients require a more extensive re-evalua-
tion of both the diagnosis and causal factors, and a
paradigm shift is warranted. The following sections
outline pharmacotherapy processes for patients
with partial response and non-response patterns.
Partial response. If remission is still not achieved
after an appropriate time, an iterative process is
necessary to achieve further symptom remission
and a better outcome. First, there should be a
review of the diagnosis to determine whether anti-
depressant medication is necessary and whether
there are any factors that could be maintaining the
depression.
Second, make sure that the dosage was opti-
mized with the current antidepressant [TCAs, ven-
lafaxine and escitalopram generally have
antidepressant activity across a broader dose range
(29–31)] and, finally, adherence was appropriate. If
the dose was not optimized, increase the dose. If,
after assessing the necessary factors, it transpires
that further improvement is unlikely on the current
antidepressant, the first treatment strategy that
should be considered is that of augmentation (refer
to the section ‘Combination and augmentation’).
Augmentation is the preferred course of action
over switching treatments because when some level
of improvement has already occurred, enhance-
ment of an ongoing treatment is ideal (28). Fur-
ther, switching is likely to introduce the added risk
of relapse because of withdrawal of the primary
antidepressant (Fig. 4).
Non response (C)
Delayed response*
(A2)
Par al response (B)
Delayed  & Par l
response (B2)
Remission (A)
TimeWeek 4a on of
treatment
Week 12
Return to func oning
High
impairment
Fig. 2. Schematic representation of potential response pat-
terns following an initial antidepressant treatment. *Delayed
response followed by remission.
Poor response (C)
High impairment
Successive response
with eventual
remission (A)
Plateau (B)
No response (D)
Return to func oning
Fig. 3. Long-term response patterns to treatment.
11
Pharmacological management of depression
Once the patient has been on the augmenting
agent for a month, evaluate the progress using a
validated scale. If marked improvement is present,
continue with treatment and assess again in a
month with the goal of reaching remission. If
remission is achieved, the augmenting agent should
be tapered down after a month of remission. If the
symptoms plateau with the augmenting agent, con-
sider stopping the augmenting agent and switching
the primary agent. When switching antidepres-
sants, carefully choose a new antidepressant with
evidence for superiority to the initial antidepres-
sant. If remission is not achieved by 3 months, a
paradigm shift is warranted. Identify and investi-
gate any unique factors that may be contributing
to the patient’s depression, including any social,
lifestyle or other variables that may influence the
delay in treatment progression. Also consider that
the treatment algorithm (Fig. 5) and clinical man-
agement and therapeutic strategies that are com-
monly used may not be appropriate for the
patient.
Treatment resistance/non-response. Despite a clini-
cian’s best effort to subtype and tailor a patient’s
treatment, some patients do not respond to treat-
ment as anticipated. When there has been no
improvement following an optimized dose of an
antidepressant, the first step should be a para-
digm shift. While taking into consideration that
the treatment algorithm may not be appropriate
for this patient, re-evaluate the diagnosis, taking
note that the patient may have developed new
symptoms, the depression is more complex than
originally thought or an alternative diagnosis
better fits the patient’s symptoms. During this
assessment, other unique and individualized fac-
tors should be taken into consideration, such as
the patient’s personality structure and lifestyle,
social factors or substance abuse. Seek advice
from colleagues if necessary. If it has been estab-
lished that the original diagnosis was accurate,
switch the patient to a new antidepressant. When
choosing a new antidepressant, consider one that
has shown evidence for superiority to the origi-
nal antidepressant (refer back to the section,
‘Selecting an antidepressant’). Before switching
the patient’s medication, consider which switch-
ing strategy (refer to the section ‘Substitute/
switching treatments’) will be utilized and
Fig. 4. Treatment algorithm for managing varying response following first-line antidepressant. Prior to commencing a new treat-
ment strategy, it is important to re-evaluate symptoms to ensure the diagnosis is correct and that pharmacotherapy is a suitable
option.
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educate the patient about the strategy and the
new medication. Once the patient has been on
the new antidepressant for a month, evaluate the
patient’s progress using a validated scale. If there
is a decline in symptoms, continue with the treat-
ment and assess again in a month with the goal
of reaching remission. If the symptoms plateau,
consider adding an augmenting agent or combin-
ing with another antidepressant (refer to the sec-
tion ‘Combination and augmentation’). If, after
further evaluation of the patient, it is determined
that the patient is still not responsive to antide-
pressant medication, the patient is considered to
have treatment resistant depression (TRD),
defined as a lack of improvement following ade-
quate trials of two or more antidepressants. With
TRD, research supports the addition of an evi-
dence-based psychotherapy (32), switching to a
neurostimulation treatment such as ECT (33),
and continuing with pharmacological strategies.
These strategies are addressed below and expand
on our previous treatment guidelines (1).
Strategies
Increase dose. As mentioned previously, before
altering any treatment, allow a trial of appropriate
duration, usually 2–6 weeks, at adequate dosage
(34, 35). Many antidepressants have a relatively
narrow therapeutic range in which the agent is
considered effective and safe, and research shows
that increasing the dose on these medications is
not any more effective (36). However, others, such
as venlafaxine and TCAs (other than nortrypti-
line), have very broad dose ranges with up to a
ten-fold increase in oral dosage. For instance, ven-
lafaxine can be safely administered at effective
doses from 37.5 to 375 mg (37). However, clinical
monitoring at high doses is especially important as
side-effects and therapy discontinuations usually
increase with dosage.
It is difficult to be exact regarding duration of
medication at any particular stage of treatment
because both clinical improvement and lack of
response are susceptible to many factors that can
alter outcome. For example, relationship and
occupational factors can often impact clinical
symptoms and either accelerate or hinder improve-
ment. Therefore, duration recommendations are
only a guide. If an adequate dose has been admin-
istered for 6 weeks and there is non-response,
switch medications, but if there is partial response,
continue the current medication for a further
6 weeks (at the same dose; but a future dose
increase can be considered if remission is not
achieved). If after 12 weeks the patient does not
improve, follow the guidelines for partial or
non-response strategies.
Combination and augmentation. Combining antide-
pressants (38), which entails either adding an
antidepressant to another antidepressant, or aug-
mentation (14), which includes adding a ‘boost-
ing’ agent to an antidepressant or increasing the
dose, are both seemingly effective strategies. Both
are commonly employed to enhance the effect of
ongoing antidepressant treatment; however, evi-
dence for either is limited, and that which is
available is constrained by the small sample sizes
of most studies and the lack of comparisons to
placebo. Clinically, combining two or more
antidepressants to enhance therapeutic effects or
decrease side-effects is common practice (39), yet
research on the efficacy of specific antidepressant
combinations is more sparse than augmentation
strategies. Both combining and augmentation
share problems concerning safety and tolerabil-
ity. Therefore, it is important to monitor the
patient carefully for side-effects and potential
toxicity.
Combination. Research has shown that combina-
tions of antidepressants can be more effective than
monotherapy without compromising tolerance (40,
41). However, long-term placebo-controlled
comparator studies are needed to substantiate a
recommendation of polypharmacy (42). When
determining which antidepressants to combine, a
rationale based on pharmacokinetic advantage or
synergistic action should inform the decision, in
addition to past experience and knowledge. For
example, venlafaxine and mirtazapine are pharma-
cologically synergistic or complementary because
of their distinct receptor profiles (43).
A double-blind randomized trial where patients
were treated with combinations of mirtazapine and
fluoxetine, or venlafaxine or buproprion showed
that these were equally effective for depression as
fluoxetine monotherapy and that they were well
tolerated (40). A recent meta-analysis found that
mirtazapine and tricyclic antidepressants in
combination with SSRIs are better than SSRI
Review
adherence &
dose
Re-assess for
Seek
consul on
Re-evaluate
diagnosis
ECT
Augment/
Combine
Clinical
M
anagem
ent
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Fig. 5. Managing partial or non-response with clinical
management and therapeutic strategies (1).
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monotherapy in achieving remission (44). Addi-
tionally, of the studies that reported drop-out rates
and side-effects, there was no difference between
the combined and monotherapy groups. Similarly,
a double-blind study that compared mirtazapine
monotherapy and paroxetine monotherapy against
a combination of both antidepressants reported
that remission rates after 6 weeks were highest for
the latter (45). However, not all research has sup-
ported the use of combinations and not all combi-
nations are pharmacologically sound (34).
Augmentation. Similar to combining antidepres-
sants, augmenting agents, such as lithium, T3 (46–
48) and some antipsychotics, can enhance the effect
of an antidepressant, especially in treatment strate-
gies for TRD. T3 is beneficial for patients with
subclinical hypothyroidism who suffer from
depression as a consequence. However, T3 is also
used as an augmentation agent for depressed
patients without hypothyroidism. Patients aug-
mented with T3 should be monitored in the same
way as patients with hypothyroidism, with TSH,
free T4 and T3 levels regularly checked (48).
Lithium, a widely supported and used augmen-
tation agent, is found to be more effective than pla-
cebo in augmentation of TCAs, SSRIs and other
antidepressants (49, 50). It is recommended that
lithium be administered once daily at an oral dose
that achieves plasma levels within the therapeutic
range (0.5–1.0 mEq/l) (51). If there is no response
to lithium within 7–10 days, alternative strategies
should be considered. Care should be taken when
discontinuing the use of lithium as research shows
that antidepressant augmentation by lithium
results in significantly higher relapse rates after
abrupt withdrawal (52).
Atypical antipsychotics are widely used clini-
cally as add-on agents for TRD, and in addition
to empirical evidence, research studies support
this strategy (53, 54). Placebo-controlled studies
have found that aripiprazole, olanzapine and
risperidone can be effective as augmentation
agents. These are generally administered at much
lower doses than those recommended for schizo-
phrenia and bipolar disorder (54–56), but this
practice is off-label and these agents are not for-
mally indicated for augmentation. Further,
adverse effects of these agents must be closely
monitored, as weight gain, potential metabolic
syndrome and extrapyramidal side-effects are of
great concern, especially in the context of long-
term therapy.
Substitution/switching medication. There are two
main considerations when switching antidepres-
sants: first, which antidepressant to trial next and
second, which strategy to employ when switching.
Switching antidepressants. Randomized control tri-
als have found that switching to a different antide-
pressant improves response and remission rates
when switching for both non-response (57) and
intolerability reasons. Switching within a class (e.g.
from one SSRI to another) is no more effective
when compared to switching out of class (e.g. from
an SSRI to a non-SSRI) (28, 58, 59), but if treat-
ment has been curtailed (e.g. medication has only
been taken for a few days) because of side-effects,
then switching within a class to another agent may
be a worthwhile option.
The majority of patients begin with a first-line
antidepressant, such as an SSRI. Patients who are
intolerant to the initial SSRI often benefit from a
second SSRI. It is recommended that patients use
a lower dose of the second SSRI initially, and it
may be necessary to taper the first SSRI for a
longer period (e.g. switching from citalopram to
escitalopram can be done immediately; switching
from fluoxetine to another antidepressant, wash-
out period of at least a week is suggested before
commencing the second agent at a lower dose).
However, if the patient was non-responsive to the
initial SSRI, switching out of class to a SNRI (i.e.
venlafaxine), norepinephrine-dopamine reuptake
inhibitor (NDRI) or TCA is recommended (58,
60). Switching to a TCA carries the benefit of
higher response rates but is disadvantaged by
greater risk of side-effects. If a patient begins with
a TCA, which is uncommon, switching to another
TCA has the advantage that a switch can occur
without a wash-out period, and the dose on the
new TCA can remain the same. As SSRIs are typi-
cally the starting point for antidepressant treat-
ment, the majority of research examines the switch
from SSRIs to another antidepressant. Therefore,
there is a lack of research evidence for other
combinations but most combinations have been
supported.
Switching strategies. There are three main strate-
gies that should be considered when deciding the
best way to switch medications: i) overlap medica-
tions, ii) taper or stop/start medications; and iii)
have a washout period. The most common strategy
utilized in practice is to introduce and withdraw
medication gradually to minimize any un-medi-
cated period and avoid the risk of the serotonin
syndrome. However, the preferred switching strat-
egy chosen should depend on the degree of
response achieved from the initial antidepressant
trial (Fig. 6).
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(A) Concurrent switch: Changes in dose of both
medications are implemented simultaneously, thus,
overlapping medications. Although this option
offers the advantage that the individual is always
medicated, there is an increased likelihood of inter-
actions and side-effects because the medications
are administered jointly.
(B) Overlapping switch: Dose changes are only
implemented in one medication at a time. The ini-
tial medication is continued at full dose while grad-
ually commencing the new medication. Begin
tapering the medication that is being substituted
once optimal dose has been met on the new medi-
cation. This strategy is preferred for partial
response because the cross-over is important to
help retain any benefit achieved from the initial
medication thus far. Similar to concurrent switch,
there is an increased risk of interactions and side-
effects because the medications are overlapped.
However, iatrogenic side-effects are more easily
identified because only one medication is modified
at a time.
(C) Sequential switch: Taper the initial medication
and once this has been fully withdrawn, gradually
introduce and titrate the new medication to opti-
mal dosage. This option is the cleanest way of
substituting one medication for another but takes
much longer, especially if it also includes a wash-
out period. This option also increases the chance
of worsening because there is a considerable period
when medication is at a subtherapeutic dose.
Therefore, this strategy is preferable for those who
did not respond to the initial medication, because
this switch can be done quickly without a washout
period and has the advantage of not overlapping
medications, which increases side-effects. However,
switching to, or from, an MAOI requires a clear
washout period of at least a week to avoid the risk
of severe drug–drug interactions.
Electroconvulsive therapy (ECT)
Electroconvulsive therapy involves applying elec-
trical current to the brain to induce a convulsion
(seizure) and is an effective alternative treatment
option in cases of marked severity, risk or ongoing
non-response to medication or psychological treat-
ments (33, 61–63). The recommended frequency is
two to three times per week under monitored con-
ditions to achieve rapid and effective antidepres-
sant effects (64, 65). Of note, the speed of response
is usually faster with three administrations per
week; however, the degree of cognitive impairment
is likely to be greater even if the overall number of
ECT treatments is the same (64). ECT should be
used in conjunction with ongoing antidepressant
treatment (66). The advantage of this strategy is
that it decreases the frequency of early post-ECT
relapse, which can be quite high in the first
6 months if ECT is used on its own (67). If concur-
rent antidepressant treatment is not used with
ECT, an antidepressant trial should be reintro-
duced following ECT treatment as antidepressants
are often effective after ECT, even if they were not
particularly beneficial prior.
Overall, ECT is very effective, with response
rates of up to 80–90% (68), but is considerably
lower for patients who have failed to respond to
adequate antidepressant medication trials (69).
However, the lower response rates in these
instances may reflect the greater severity of the ill-
ness, as ECT is commonly used as a last resort
once antidepressants have failed. Of note, ECT is
more effective than antidepressant monotherapy
for patients with melancholia (70) and especially
those with psychotic depression (68). Additionally,
ECT is also recommended for treating severe
depression during pregnancy as it poses less of a
risk to the foetus and mother (71) compared with
antidepressant use (72, 73).
Novel treatments
Other options that include neurostimulation are
repetitive transcranial magnetic stimulation
(rTMS), vagus nerve stimulation (VNS) and deep
*Non- response
al response
(b) Overlapping switch (a) Concurrent switch 
(c) Sequential switch 
Fig. 6. Schematic representation of strategies for switching
antidepressant medication. The preferred switching strategy
chosen should depend on the degree of response achieved from
the initial antidepressant trial: (a) changes in dose of both med-
ications are implemented simultaneously, thus, beneficial for
partial response; (b) dose changes are only implemented in one
medication at a time, while holding the initial medication con-
stant at the original dose until the second medication has
reached optimal dose; thus, this strategy is suitable for partial
response; (c) this option is the safest way (least likely to cause
any interactions) of substituting one medication for another
and is preferable for those who did not respond to the initial
medication.
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brain stimulation (DBS), the latter two of which
are more invasive than ECT. rTMS involves gener-
ating a superficial current by way of electromag-
netic induction in the dorsolateral prefrontal
cortex. Unlike ECT, it has shown minimal adverse
neurocognitive effects (74). The VNS device has a
good safety profile but the efficacy is still being
evaluated. DBS involves implanting a stimulating
electrode in a specified area of the brain. Early
results in open-label trials of DBS use for depres-
sion treatment are promising (75–77), but need
RCT evidence before it can be recommended for
clinical practice.
Substantial resources are being devoted to the
genetic epidemiology of depression and are
another source for novel treatment options for
depression. Although the overall genetic contribu-
tion to depression is likely to be minor (78),
preliminary research suggests that efficacy of
antidepressants may be predicted by genetic mark-
ers (79), yet more research is necessary to replicate
these findings. Escitalopram response was pre-
dicted by a marker in the gene encoding interleu-
kin-11 and IL-6 gene, in which the latter has been
established as a candidate gene for depression (80).
Additionally, response to nortriptyline has been
shown to be associated with the UST gene,
although this gene has yet to be an established
genetic marker for depression. Brain-derived neu-
rotrophic factor (BDNF) has been examined as a
susceptibility locus for the development of depres-
sion, but the results have been inconclusive as there
are contradictory findings in recent research (81–83).
Additionally, the gene–environment hypothesis
focused on the link between the serotonin trans-
porter-linked polymorphic region (5-HTTLPR)
and stressful life events on increased risks of
depression. Although the results suggest that per-
sistent depression increases with this specific gene x
environment interaction, further research has
failed to replicate these findings (84, 85).
Importance of re-evaluating diagnosis
It is unlikely that core features of major depres-
sion, such as depressed mood and feelings of
hopelessness, occur in isolation from symptoms of
anxiety, substance misuse, personality disorders
or eating disorders. In fact, a large proportion
(estimated 50–70%) of patients with depression
report anxiety symptoms (86–88). These com-
monly occurring comorbidities complicate diagno-
sis and treatment and contribute to a poorer
prognosis (89, 90). Therefore, re-evaluating the
diagnosis following partial and non-response to
antidepressant treatment is crucial, keeping in
mind that depression may not be the primary or
sole diagnosis.
Bipolar depression is another complex layer that
should be explored when diagnosing and treating,
as 10–20% of patients diagnosed with unipolar
depression will experience hypomania or mania in
the course of their illness, resulting in a revision of
diagnosis to bipolar disorder (91, 92). There is also
growing evidence to suggest that hypomanic symp-
toms commonly occur in a subset of patients with
depression and these contribute to treatment non-
response (93). Predictive factors for bipolar disor-
der that have been robust across studies include
early age at illness onset (94–96), presence of psy-
chosis (94, 97, 98) and family history of mania (94,
95, 97–99). Even if manic symptoms were previ-
ously explored, critically examine the patient’s past
and recent history specifically targeting symptoms
of mania or hypomania.
Paradigm shift
In the event that the iterative treatment options
have been explored and the patient is still non-
responsive, consider individual factors, unique
characteristics and other variables that may be
influencing treatment resistance. Additionally,
consider other treatment options outside of the
treatment algorithm. The patient may have devel-
oped new symptoms; the depression is more com-
plex than originally thought; or there are social/
lifestyle factors that may be a contributing factor.
For example, since the commencement of the ini-
tial antidepressant, the patient may have lost his
job, which in turn negatively affects his relation-
ship and housing situation. In this instance, an
overall reassessment is needed while taking into
consideration the patient’s lifestyle, psychological
treatments, substance abuse and/or more aggres-
sive treatment options (e.g. ECT). It is possible
that the original diagnosis may be wrong. Return-
ing to the 5P Model and reassessing the patient’s
problems are in the best interest for the patient and
may open up new possibilities for treatment. If it
has been established that the original diagnosis is
correct and the patient’s symptoms are non-
responsive to the previously suggested treatment
options, novel treatment options may be warranted.
Remission/recovery
Duration of treatment. Long-term antidepressant
treatment should be considered on an individual
basis, while taking into consideration the risks of
continued medication use and benefits of preventa-
tive care. Research recommendations suggest that
16
Malhi et al.
antidepressant treatment should continue for at
least 1 year following the onset of symptoms for
an initial episode and at least 2 years if the patient
carries any risk factors, such as having many prior
depressive episodes, particularly if they are severe,
chronic and difficult to treat with residual symp-
toms, significant comorbidity or the patient is of
older age (100–103). If psychotic features are pres-
ent, then continue treatment for up to 3 years
(104). Meta-analysis results suggest that to main-
tain remission, the treating dose should be contin-
ued; decreasing the dose significantly increases
relapse/recurrence rates (105).
During antidepressant maintenance, the
patient’s condition should continually be assessed
as the risk of relapse is relatively high and is
increased by a variety of factors (Fig. 7). Relapse
rates are highest immediately following remission
and diminish with time (106). In addition to anti-
depressant treatment, cognitive behavioural ther-
apy (CBT) has shown long-term effects in
preventing relapse and recurrences. Thus, integrat-
ing CBT with antidepressant treatment may
decrease both relapse rates and the need for long-
term antidepressant maintenance (32).
Ensuring adherence. Patient improvement with
pharmacotherapy heavily relies on adherence;
thus, it is crucial that adherence is actively
addressed and monitored. Patients who are
depressed are unmotivated and feel down, so
engaging in an unnatural routine of taking medica-
tion, which is an anomalous habit for healthy indi-
viduals, is even more difficult for those who are
depressed. To increase adherence, educational
interventions should be used in conjunction with
behavioural changes in order to gain maximum
benefit. Complex behavioural changes are the most
effective in improving antidepressant medication
adherence (107). Prior to starting antidepressant
treatment, both the physician and patient must
understand what the ultimate goal of treatment is
and why medication is important. The patient
should be clear of what is necessary to achieve this
goal, including what should be done if a dose is
missed. Missing a dose should be actively
addressed so the patient understands that missing
a dose does not result in failed treatment, but
rather, repeatedly neglecting the prescribed dosage
causes ineffective treatment. Patients should be
advised not to ‘double-up’ their medication should
they miss a dose. When assessing the patient at
each visit, physicians should include questions
regarding adherence, which should become routine
during each visit. Although side-effects and toler-
ance are often viewed as negative, they are another
indicator of patient adherence. Thus, if the patient
reports no side-effects, the patient’s adherence
should be questioned. When side-effects such as
weight gain or sexual dysfunction compromise
adherence to medication, it is worthwhile switching
to an antidepressant with a more favourable side-
effect profile, such as agomelatine that does not
carry these side-effects (108, 109), to ensure main-
tenance of treatment.
Titrating treatment. Treatment guidelines recom-
mend upward dose titration during the initial
stage of antidepressant treatment (110–112).
Titration upwards normally involves increasing
the antidepressant dose gradually while monitor-
ing for efficacy, and as mentioned, it is an iterative
process that may involve many dose increases
depending on the antidepressant being prescribed.
However, the starting dose needs to be taken into
consideration when weighing the advantages and
disadvantages of titration. The initial antidepres-
sant dose is likely to vary depending on whether
the clinician has planned titration a priori or has
made a decision to increase dosage post hoc. The
latter is usually the consequence of a partial or
non-response. In general, titration is a useful
approach for reducing side-effects, but it delays
the achievement of a therapeutic dose, and the
likelihood of a clinical response. However,
research shows that patient adherence is signifi-
cantly greater when patients begin on a low dose
with future titration compared to patients who
commence treatment at therapeutic levels.
Patients who commenced antidepressant treat-
ment at a dose less than or equal to the dose rec-
ommended in the APA guidelines and who
titrated their antidepressant dose within 60 days
were 2.6 times more likely to adhere to treatment
than patients who began at a dose recommended
Presence of psychosis
Treatment resistance
Time
Concurrent factors
Gender – Female
Life events/social stress
Comorbid medical illness
Residual symptoms
on of episode
Severity of
depression 
Fig. 7. Factors increasing the risk of acute relapse in depres-
sion. Concurrent factors should be taken into consideration
when choosing treatment options. Note. Specific factors that
increase the risk of relapse are labelled at the point of where
they are likely to impact treatment.
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by APA guidelines. These findings apply to a
range of SSRI and SNRI medications (113).
Commencing a patient on antidepressant levels
at, or less than, the recommended dose with the
intention to titrate treatment is particularly useful
for patients who are frail (e.g. elderly, those with
comorbid medical illness) (114, 115) or when
commencing certain classes of antidepressants. For
example, tricyclic antidepressants need to be
titrated because of potential cardiac toxicity associ-
ated with peak plasma levels (116). Additionally, in
practice, patients on SSRIs and SNRIs can
decrease their risk of transitory side-effects by com-
mencing treatment on low doses and titrating the
dose slowly to reach therapeutic levels (115, 117).
Although this initial titration of treatment
increases the complexity of management, it does
foster closer clinician follow-up and ensures adher-
ence. Therefore, the combined effect of titration
and regular clinician follow-up should significantly
improve patient outcome.
Discussion
Psychological/social/lifestyle factors
Depression is a complex neuropsychiatric disorder
that is unlikely caused solely by biological factors,
but rather includes psychological, personality and
social components (118). Therefore, the election of
treatment for depression should incorporate phar-
macological, psychological and lifestyle aspects
and be individually tailored for the patient. Our
companion paper on ‘Psychological Management
of Unipolar Depression’ (3) explains in more detail
various therapeutic approaches and appropriate
treatment appraisal based on presenting symptoms
and patient characteristics/preferences and history.
The likely outcome from treatment also needs to
consider the patient’s lifestyle and personal
choices. Our companion paper on the ‘Lifestyle
Management of Unipolar Depression’ (4) will also
assist clinicians in diminishing the likelihood of
partial and non-response. Moreover, the inclusion
of all three recommendations is ideal in the mainte-
nance phase of treatment.
Integration of care
Role of primary care physician and general practi-
tioner. Primary care physicians are pivotal to
mental health care, especially if they have been
treating the patient long term. The amount of
involvement the primary physician has with treat-
ing the patient’s depression depends on the com-
plexity of the patient’s illness and the level of
involvement of the psychiatrist. Patients who are
treated by a psychiatrist on a regular basis will
have less contact with their primary physician for
the depression treatment, yet the GP should con-
tinue to be aware of the treatment in case of emer-
gency and the patient needs medical assistance on
short notice. Patients with mild cases of depression
are likely to continue seeing their primary physi-
cian for monitoring and treatment maintenance as
they are less likely to engage with a psychiatrist full
time. Regardless of the patient’s severity, the psy-
chiatrist and primary physician should communi-
cate with each other regarding changes in mental
or physical state and changes in treatment.
Family and friends. Depressed patients are likely to
experience stress associated with their family and
other relationships, which is often a factor contrib-
uting to the patient’s illness (119). However, posi-
tive social networks are fundamental for patient
improvement, and these relationships should be
maximized throughout treatment.
In conclusion, the pharmacotherapy of depres-
sion is a complex process because it is a heteroge-
neous disorder and each individual, when affected,
requires consideration of unique factors. In addi-
tion, effective treatment relies on both empirical
evidence and clinical experience. In practice, first
and foremost, adherence is essential, and this needs
to be fully appreciated by the patient and regularly
monitored by the physician. Response rates to ini-
tial antidepressant treatment are lower than those
reported in clinical trials and as such follow-up
with subsequent treatments is often necessary.
Careful and comprehensive clinical assessment of
the symptomatic profile is critical and should
include the use of a standardized rating scale (e.g.
HAM-D) to gauge severity and track change.
Although there are many strategies and within
these there are multiple options, the extant
research suggests that adding an augmentation
agent and switching to a new antidepressant are
effective tactics and that these are best suited for
partial and non-responders respectively. In cases
of TRD, it is important to consult with colleagues
to gain a different perspective and consider alter-
nate treatment paradigms. It is also useful to thor-
oughly re-evaluate the diagnosis noting that there
may be additional contributing factors as the ill-
ness has most likely evolved from the time of initial
presentation.
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